New Labeling Reagents for Genetic Analysis

Information

  • Research Project
  • 6484834
  • ApplicationId
    6484834
  • Core Project Number
    R43CA096451
  • Full Project Number
    1R43CA096451-01
  • Serial Number
    96451
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/1/2002 - 23 years ago
  • Project End Date
    4/30/2003 - 22 years ago
  • Program Officer Name
    OZENBERGER, BRADLEY
  • Budget Start Date
    5/1/2002 - 23 years ago
  • Budget End Date
    4/30/2003 - 22 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
  • Award Notice Date
    5/1/2002 - 23 years ago

New Labeling Reagents for Genetic Analysis

DESCRIPTION (provided by applicant): This Small Business Innovation Research Phase I project aims to investigate the feasibility of developing new, sensitive, accurate, and reliable detection methods for genomic DNA or RNA samples that are essential for genomic microarray analysis. If successful, the proposed research will help provide breakthroughs needed to advance the promising medical uses of genomic analysis to determine the pattern of gene expression in live cell assays. In Phase I of this project, Marker Gene Technologies proposes to establish the feasibility of the technology by preparing new labeling reagents and systems capable of directly modifying DNA or RNA oligomers for ultrasensitive fluorescence or chemiluminescent detection. These labeling reagents will be assayed in vitro for their ability to monitor gene expression events in response to biological effects on cell function and to monitor the change in gene expression upon application of drugs and bioactive compounds in a cell-specific manner. In Phase II, these and additional detection reagents and methods will be further tested in a variety of pre-clinical applications for genomic expression analysis combined with drug application. PROPOSED COMMERCIAL APPLICATION: The success of this project opens up enormous commercial possibilities in the fields of medical intervention in genetic diseases, genetic screening of new proteins and drugs in cell-culture systems, and new anti-bacterial and anti-viral agent discovery. In addition, it contributes new information and techniques for basic cell-biology research, and the labeling reagents and techniques produced can be marketed for these research and commercial uses.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    99982
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:99982\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MARKER GENE TECHNOLOGIES
  • Organization Department
  • Organization DUNS
  • Organization City
    EUGENE
  • Organization State
    OR
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    974031992
  • Organization District
    UNITED STATES